Home > Insider Trading > Filing (0000899243-17-008208)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1180428	J Mark Levin	C/O Third Rock Ventures, Llc 29 Newbury Street, 3Rd Floor Boston MA 02116		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-16	24,800	$40.74	116,444	No	4	S	Direct
Common Stock	Disposition	2017-03-16	5,200	$41.55	111,244	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,453,753	Indirect	See footnote

Footnotes

This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.33 to $41.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.34 to $41.84, inclusive.
These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.